Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries a,b c d a,b Meena Gorowara , David Burger , Andrew Hill and Kiat Ruxrungtham HIV Netherlands Australia Thailand Research Purpose of review Collaboration (HIV-NAT), Thai Red Cross AIDS b The costs associated with antiretroviral therapy are becoming a major concern for the Research Center, Clinical Research Laboratory (CRL), Chulalongkorn Clinical Research Center (ChulaCRC), treatment of HIV-infected patients in resource-limited countries. Potential risk for the Department of Medicine, Faculty of Medicine, increase in toxicity due to higher drug exposure among Asians is also a concern. In this Chulalongkorn University, Bangkok, Thailand, Department of Clinical Pharmacy and Nijmegen article, we discuss the studies performed using low-dose antiretroviral therapy as an Institute for Infection, Inflammation & Immunology effective and well tolerated strategy. (N4i), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands and Department of Recent findings Pharmacology, University of Liverpool, Liverpool, UK The studies reviewed demonstrate that dose reduction of antiretroviral therapy provides Correspondence to David M. Burger, Pharm D, PhD, adequate plasma concentrations and effective immunological and virological responses Department of Clinical Pharmacy, 864 Radboud in, mainly, a Thai population compared with whites. The differences in these University http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries

Ruxrungtham, Kiat
Current Opinion in HIV and Aids , Volume 5 (1) – Jan 1, 2010
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/pharmacokinetics-of-low-dose-protease-inhibitors-and-efavirenz-in-low-2MHyIEG2h0

References (33)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3283339caf
pmid
20046153
Publisher site
See Article on Publisher Site

Abstract

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries a,b c d a,b Meena Gorowara , David Burger , Andrew Hill and Kiat Ruxrungtham HIV Netherlands Australia Thailand Research Purpose of review Collaboration (HIV-NAT), Thai Red Cross AIDS b The costs associated with antiretroviral therapy are becoming a major concern for the Research Center, Clinical Research Laboratory (CRL), Chulalongkorn Clinical Research Center (ChulaCRC), treatment of HIV-infected patients in resource-limited countries. Potential risk for the Department of Medicine, Faculty of Medicine, increase in toxicity due to higher drug exposure among Asians is also a concern. In this Chulalongkorn University, Bangkok, Thailand, Department of Clinical Pharmacy and Nijmegen article, we discuss the studies performed using low-dose antiretroviral therapy as an Institute for Infection, Inflammation & Immunology effective and well tolerated strategy. (N4i), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands and Department of Recent findings Pharmacology, University of Liverpool, Liverpool, UK The studies reviewed demonstrate that dose reduction of antiretroviral therapy provides Correspondence to David M. Burger, Pharm D, PhD, adequate plasma concentrations and effective immunological and virological responses Department of Clinical Pharmacy, 864 Radboud in, mainly, a Thai population compared with whites. The differences in these University

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jan 1, 2010

There are no references for this article.